SANTA CLARA, Calif., June 3 /PRNewswire/ -- Applied Imaging Corporation
(Nasdaq: AICX) announced the closing of a private placement of 3,333,331
shares of its Common Stock to certain accredited investors. This sale
represents a $10 million placement at a purchase price of $3.00 per share.
The proceeds from the sale of the shares will be used for working capital and
general corporate purposes.
Jack Goldstein, Ph.D., President and CEO of Applied Imaging, commented,
"We are very pleased with the number of parties interested in participating in
this private placement. Several of the participating investors are current
stockholders in Applied Imaging and their continued interest is indicative of
the confidence they have in the company. This private placement strengthens
our financial position and will allow us to continue advancing our prenatal
screening program."
Applied Imaging Corporation develops, manufactures and markets automated
clinical analysis systems used by laboratories for the diagnosis of prenatal
and other genetic disorders. The company markets its products worldwide.
Applied Imaging is developing a proprietary prenatal test for screenings of
genetic abnormalities by isolating fetal cells from a routine maternal sample.
This new test is designed to improve current prenatal screening techniques by
providing an accurate and cost effective procedure without the risk of
miscarriage associated with invasive prenatal testing. Applied Imaging is a
publicly traded company listed on the Nasdaq National Market System under
the symbol AICX.
SOURCE Applied Imaging Corporation
 back to top
CONTACT:
Jack Goldstein, President and CEO, or Donna
Dickinson, Investor Relations, both of Applied Imaging
Corporation, 408-562-0250; or General Info, Ann Trunko, or
Investor Contact, Kate Rajeck, both of The Financial Relations
Board, 415-986-1591
NOTE TO EDITORS: For more information on Applied Imaging via fax
at no cost, dial 800-PRO-INFO (908-544-2850 outside the U.S.),
ticker symbol AICX.
|
